2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1790 Duration of response to iopofosine I 131 in patients with relapsed/refractory Waldenström macroglobulinemia by prior lines of therapy: Results from the pivotal phase 2b clover-wam study

Sikander Ailawadhi, MD, Maria Gavriatopoulou, MD2, Jennifer L Peterson, MD3, Ioannis Ntanasis-Stathopoulos, MD4, Ariel F. Grajales-Cruz, MD5, Aimaz Afrough, MD6, Yair Levy, MD7, Judith Trotman, FRACP, FRCPA, MBChB8, Kimberley Doucette, MD9, Jorge J Castillo, MD10, Francisco Hernandez-Ilizaliturri, MD11, Ajay K Nooka, MD, MPH12, Shirley D'Sa, MD13, Ralph Vincent Boccia, MD14, Harsh Parmar, MD15, Carlos Fernandez de Larrea, MD, PhD16, Guldane Cengiz Seval, MD, PhD17, Sheeba Koshy Thomas, M.D.18, Kate Oliver, BS19, Jarrod Longcor, MD20, Larry D Anderson Jr, MD, PhD21
1 Mayo Clinic, Jacksonville, Florida, United States
2 Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece
3 Mayo Clinic, Jacksonville, Florida, United States
4 Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece
5 Moffitt Cancer Center, Tampa, Florida, United States
6 UT Southwestern Medical Center, Dallas, Texas, United States
7 Texas Oncology, Dallas, Texas, United States
8 Concorde Repatriation General Hospital, Sydney, Australia
9 MedStar Georgetown University Hospital, Washington, District of Columbia, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
12 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
13 University College London Hospital, London, United Kingdom
14 The Center for Cancer and Blood Disorders, North Bethesda, Maryland, United States
15 John Theurer Cancer Center-Hackensack University Medical Center, Hackensack, New Jersey, United States
16 Hospital Clinico de Barcelona, Barcelona, Spain
17 Ankara University Faculty of Medicine Cebeci Hospital, Ankara, Turkey
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 Cellectar Biosciences, Florham Park, New Jersey, United States
20 Cellectar Biosciences, Florham Park, New Jersey, United States
21 UT Southwestern Medical Center, Dallas, Texas, United States

Background: Waldenström macroglobulinemia (WM) is an incurable, indolent B-cell lymphoma for which most patients (pts) require multiple lines of therapy, including Bruton tyrosine kinase inhibitors (BTKi). Pts who progress after BTKi therapy, particularly BTKi-refractory pts, have limited options and historically poor outcomes. Iopofosine I 131 is a targeted radiotherapeutic that selectively delivers iodine-131 to malignant cells via a phospholipid ether carrier. This post hoc subgroup analysis evaluated duration of response (DoR) among responders in the CLOVER-WaM study according to the number of prior lines of therapy (PLoT).

Methods: In the pivotal Phase 2b CLOVER WaM study, eligible WM pts received ≥2 PLoTs and had measurable disease for assessment of response by the modified IWWM-VI. Treatment (tx) consisted of 2 cycles of iopofosine I 131 administered at 15 mCi/m2 on days 1 and 15 of each 57-day cycle. Supportive care with growth factors and transfusions was permitted per physician discretion.

As previously reported (Ailawadhi S, et al. 2024), 65 pts were dosed and 55 are in the efficacy evaluable population.  Of these pts, 29.1% (16/55) had 2 PLoT and 70.9% (39/55) had ≥ 3 PLoT (mean 5.1, range 3-15). Reported here are results in 46 pts with a minor response (MR), partial response (PR), very good PR (VGPR), or complete response (CR). DoR was analyzed in two cohorts (2 or ≥ 3 PLoT) in 35 pts with PR, VGPR, or CR.  DoR was defined as time from first response to disease progression or censor date and estimated using the Kaplan-Meier method, with 95% confidence intervals derived via the log-log transformation. Best overall response, BTKi exposure/refractory status, and total administered dose (mCi) were compared between cohorts.

Results: Of the 46 pts analyzed, 65.2% (30/46) had ≥ 3 PLoT (range 3 to 15) and 34.8% (16/46) had 2 PLoT. BTKi exposure was more frequent in the ≥3-line cohort than the ≤2-line cohort (73% vs. 50%), as was BTKi-refractory disease (57% vs. 44%). Best response was similar across cohorts: overall response rate was 100% (16/16) in the ≤2-line cohort and 100% (30/30) in the ≥3-line cohort, with major response (CR + VGPR + PR) achieved in 76.7% and 75%, respectively. Administered dose distribution for pts achieving a major response was comparable (≥100 mCi in 61% of pts in the ≥3 PLoT cohort vs. 58% in the 2 PLoT cohort). Median DoR was 20.6 months in the 2-line cohort (95% CI, 7.0-39 months) and was 9.9 months in the ≥3-line cohort (95% CI, 6.6 - 14 months, p=0.009).

Preliminary cytogenetic analysis suggests MYD88/CXCR4 co-mutation may be enriched among more heavily pretreated pts and associated with shorter DoR, although subgroup sizes are small (n=5-8). One pt with confirmed MYD88/CXCR4/TP53 co-mutations had the shortest DoR of 48 days.

Cytopenias were the most common tx emergent adverse event (TEAE) considered related to iopofosine I 131 by the investigator, in line with prior experience. Grade ≥ 3 thrombocytopenia was observed in 43% of pts in the 2 PLoT cohort and 87% in the ≥ 3 PLoT cohort, while Grade ≥ 3 neutropenia was seen in 30% and 63%, respectively. Non-hematologic iopofosine I 131-related TEAEs in general were Grade 1- 2 and not common. In the 2 PLoT cohort, fatigue and nausea were reported in 38% and 19% of pts, respectively. These same TEAEs were reported in 17% and 13% of pts in the ≥ 3 PLoT cohort, respectively. There were no iopofosine I 131 related deaths in either cohort.

Conclusion: Iopofosine I 131 produced high response rates and durable responses in relapsed/refractory (R/R) WM regardless of prior tx burden, including heavily pretreated, BTKi-refractory pts. In this analysis, pts receiving 2 PLoT demonstrated a longer DoR than those with ≥3 PLoT (median 20.6 vs. 9.9 months; p=0.009), a difference that may not be fully explained by differences in BTKi exposure, BTKi refractoriness, administered dose, or depth of response between groups. Exploratory analyses suggested that MYD88/CXCR4 co-mutations may be more frequent among heavily pretreated pts and could contribute to shorter DoR; however, the small sample size precludes firm conclusions.

While pts with fewer PLoTs tolerated iopofosine I 131 better than those with ≥ 3 PLoTs, likely due to differences in marrow reserves, response depth and frequency were consistent regardless of tx history. These findings support the clinical activity of iopofosine I 131 in R/R WM and warrant confirmation in larger studies.

Sikander Ailawadhi, MD: BMS - Research Funding; Xencor - Research Funding; Cellectar - Research Funding; Janssen - Research Funding; Ascentage Pharma Group Inc. - Research Funding; Amgen - Research Funding; Pharmacyclics - Research Funding; AbbVie - Research Funding; GSK - Research Funding; GSK - Consultancy (Includes expert testimony); Cellectar - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony)